Published: April 2022 | Report Code: 12285 | Available Format: PDF
The precision cardiology market size stood at $1,011.5 million in 2021, and it is expected to rise at a growth rate of 12.8% during 2021–2030. The market growth is supported by the reducing cost of sequencing methods, growing awareness of early screening of cardiovascular diseases (CVDs), and rising burden of CVDs. For instance, according to the World Health Organization (WHO), around 17.9 million people died from CVDs in 2019, accounting for around 31% of total deaths worldwide.
Moreover, the global market is undergoing a significant change with regard to advancements that have already taken place and are currently invading the market space. Additionally, with the emergence of advanced molecular technologies, there is immense potential for precision cardiology in emerging markets.
During the COVID-19 pandemic, the market witnessed a massive drop in year-on-year growth, which was majorly attributed to the temporary halt in research activities pertaining to precision cardiology coupled with the low influx of patients in hospitals due to the changed healthcare priorities. Also, manufacturers delayed their product launches, owing to the ensuing restrictions.
Since 2021, market players have adopted several strategies to bolster sales and negate the impact of the pandemic, which include aggressive marketing and discounted prices offered for existing portfolios. For instance, in June 2021, GENinCode partnered with EVERSANA Life Sciences LLC as its commercial partner to access the U.S. market for the GENinCode portfolio of polygenic CVD products, specifically focused on genetic risks. Moreover, with the restrictions gradually being removed from several regions around the world, coupled with research activities resuming normalcy, the market will recover in the coming years.
Report Attribute | Details |
Historical Years |
2017-2022 |
Forecast Years |
2022-2030 |
Market Size in 2021 |
$1,011.5 Million (Estimated) |
Revenue Forecast in 2030 |
$2,998.4 Million |
Growth Rate |
12.8% CAGR |
Report Scope |
Market Trends, Drivers, and Restraints; Revenue Estimation and Forecast; Segmentation Analysis; Impact of COVID-19; Companies’ Strategic Developments; Market Share Analysis of Key Players; Company Profiling |
Segments Covered |
By Offering, By Sample, By Technology, By Application, By End User, By Region |
Explore more about this report - Request free sample pages
As of 2021, the precision cardiology market was subjugated by the service category, holding a market share, of around 80%. This is primarily attributed to the rising emphasis on the adoption of precision medicine in clinical settings. Moreover, underlying factors, such as sedentary lifestyle, unhealthy diet, obesity, and the growing population of pre-diabetics and diabetics worldwide, are imposing a combinatorial effect upon the global burden of CVDs, which results in the rising precision diagnosis’ services demand.
The non-blood samples category is predicted to grow at a healthy CAGR in the market during 2021–2030. This can be primarily due to the clinical utilities of non-blood samples, which have been well-established and documented for conducting precision tests. Moreover, the companies operating in the market are actively involved in developing advanced tests based on non-blood-based samples, such as saliva and buccal swab specimens, which, in turn, boost the sales of these samples.
The sequencing category accounted for the highest revenue, over $600 million, in 2021. The category is also expected to witness the same trend in the coming years. This is due to its clinical advantages, including higher accuracy, low cost of sequencing, broader coverage, and high scalability.
The cardiomyopathy application accounts for the largest demand for precision cardiology tests, and the category is expected to generate a revenue of over $800 million by 2030. This is attributed to the increasing global incidence of various types of cardiomyopathies, the rising focus on research for the development of novel molecular diagnostic solutions, and the surging adoption of precision medicines, among others. For instance, according to the American College of Cardiology, the global prevalence of alcoholic cardiomyopathy was 708,000 cases in 2019.
Hospitals and diagnostic laboratories are at the forefront of being the primary end users of precision cardiology testing for the diagnosis of CVDs. Hospitals and diagnostic laboratories offer a wide range of expertise in pathology and advanced laboratory diagnostics for precision testing. These laboratories include state-of-the-art testing services required for conducting in-depth biomarker analysis with a strong foundation of consultation for various CVDs.
In 2021, North America held the highest revenue share in the precision cardiology market. This is ascribed to the presence of major market players in the U.S. and the significant adoption of advanced products and services in clinical and research settings. Moreover, government initiatives targeting the correlation of genetic biomarkers with cardiovascular care have significantly propelled the overall market scenario in the region.
Moreover, the U.S. Food and Drug Administration (FDA) and the Clinical Laboratory Improvement Amendments (CLIA) have played key roles in the development of effective and appropriate guidelines and policies for the adoption of precision medicinal products and services in the region. Further, with a highly dynamic market along with a consistently rising number of emerging companies offering end-to-end services, the North American market is likely to continue leading throughout the prediction period.
Factors such as the geriatric population, sedentary lifestyle, unhealthy eating habits, diabetes, tobacco consumption, and family history of CVDs are some prominent risk factors imposing a combinatorial impact upon the high prevalence of CVDs. For instance, according to the Center for Disease Control and Prevention (CDC), about 659,000 people in the U.S. die from heart disease each year. Moreover, as per the Heart Foundation, more than 4 million Australians are having CVDs. In addition, according to the European Heart Network, CVDs cause 3.9 million deaths each year in Europe.
Diagnostics is the first step toward reducing the incidence of CVDs. With the ever-evolving knowledge about molecular alterations associated with CVDs, including hereditary cardiac conditions, there is an urgent need for the identification of efficient and advanced diagnostic techniques for reducing the clinical burden caused by such diseases. Moreover, various end users, such as hospitals and diagnostic laboratories, are implementing molecular diagnostic tests for the assessment of CVDs to offer better clinical insights, further providing early treatment solutions.
Key players in the precision cardiology industry are highly involved in product launches and approvals to gain a competitive edge. For instance:
The report offers comprehensive market segmentation analysis along with market estimation for the period 2017–2030.
Based on Offering
Based on Sample
Based on Technology
Based on Application
Based on End User
Geographical Analysis
In 2030, the value of the precision cardiology market will be $2,998.4 million.
Cardiomyopathy is the largest category under the application segment of the precision cardiology industry.
The major precision cardiology market drivers are the reducing cost of sequencing methods, growing awareness of early screening of cardiovascular diseases (CVDs), and rising burden of CVDs.
North America is the largest precision cardiology market.
Most precision cardiology market players are adopting product launches and approvals strategy to sustain their business growth.
Get a bespoke market intelligence solution
Want a report tailored exactly to your business strategy?
Request CustomizationWant an insight-rich discussion with the report author?
Speak to AnalystOur dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws